Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial ; volume:130 ; number:1 ; day:30 ; month:10 ; year:2023 ; pages:43-52 ; date:1.2024
British journal of cancer ; 130, Heft 1 (30.10.2023), 43-52, 1.2024
- Urheber
-
Jo, Jung Hyun
Kim, Yong-Tae
Choi, Ho Soon
Kim, Ho Gak
Lee, Hong Sik
Choi, Young Woo
Kim, Dong Uk
Lee, Kwang Hyuck
Kim, Eui Joo
Han, Joung-Ho
Lee, Seung Ok
Park, Chang-Hwan
Choi, Eun Kwang
Kim, Jae Woo
Cho, Jae Yong
Lee, Woo Jin
Moon, Hyungsik Roger
Park, Mi-Suk
Kim, Sangjae
Song, Si Young
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41416-023-02474-w
- URN
-
urn:nbn:de:101:1-2024032510122517866439
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jo, Jung Hyun
- Kim, Yong-Tae
- Choi, Ho Soon
- Kim, Ho Gak
- Lee, Hong Sik
- Choi, Young Woo
- Kim, Dong Uk
- Lee, Kwang Hyuck
- Kim, Eui Joo
- Han, Joung-Ho
- Lee, Seung Ok
- Park, Chang-Hwan
- Choi, Eun Kwang
- Kim, Jae Woo
- Cho, Jae Yong
- Lee, Woo Jin
- Moon, Hyungsik Roger
- Park, Mi-Suk
- Kim, Sangjae
- Song, Si Young
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy
Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine
Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy
Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine
Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy
Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine